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Abstract Glutathione peroxidase 1 (Gpx1) is an endoge-
nous antioxidant enzyme. The T allele of the Pro198Leu
polymorphism in the Gpx1 (rs1050450, 198C[T) gene is
associated with reduced enzyme activity. The aim of this
study was to evaluate the association between Pro198Leu
polymorphism and risk of diabetic peripheral neuropathy
(DPN). We examined 1244 T2DM patients and 730 healthy
controls. In the patient group, 33 % had diabetic peripheral
neuropathy. All subjects were genotyped for the Gpx1
Pro198Leu polymorphism by polymerase chain reaction
and restriction analysis. A significant increase in the T
allele and TT genotype frequencies was observed in DPN
patients compared to those without DPN (OR 1.55, 95 %
CI 1.30–1.85 and 1.89, 95 % CI 1.30–2.74, respectively).
The association remained significant after correction for
age, disease duration, HbA1c and BMI. When distribution
of T allele was compared between DPN? and
DPN- subgroups and controls, OR was 1.54 for
DPN? and 1.00 for DPN- patients. In conclusion, our
findings suggest that Gpx1 Pro198Leu genotypes are sig-
nificantly associated with the risk of diabetic peripheral
neuropathy in patients with T2DM. The study provides
new clinically relevant information regarding genetic
determinants of susceptibility to diabetic neuropathy.
Keywords Gpx1  Type 2 diabetes  Peripheral
neuropathy  Pro198Leu polymorphism  Risk allele
Introduction
Diabetes mellitus (DM) is a chronic multifactorial disease
characterized by persistent hyperglycemia that is associ-
ated with increased morbidity and mortality. Increased
mortality in diabetes is due to the development of both
macrovascular and microvascular complications (Brownlee
2005). One of the frequent late microvascular complica-
tions of diabetes is diabetic neuropathy (Vinik et al. 2000;
Vincent et al. 2004). At least 50 % of patients with type 2
diabetes suffer from the most common form, diabetic
peripheral neuropathy (DPN) (Kasznicki et al. 2012). It is
characterized by inflammation and degeneration of
peripheral nerves and accompanied by pain, loss of sen-
sation and paresthesia. It predisposes to severe functional
limitations and serious complications including leg ampu-
tation (Ybarra et al. 2010; El Bghdady and Badr 2012).
DPN has a complex pathogenesis, involving vascular,
metabolic and neurochemical processes. Chronic hyper-
glycemia is involved in the development of mitochondrial
dysfunction, leading to reactive oxygen species (ROS)
overproduction (Brownlee 2001). Additional sources of
ROS in diabetes include glucose autooxidation, protein
kinase C activation, methylglyoxal formation and glyca-
tion, hexosamine metabolism and sorbitol formation. All
these factors contribute to excessive oxidative stress
(Evans et al. 2002; Robertson et al. 2004). In type 2 dia-
betes, the activity of major antioxidant enzymes such as
superoxide dismutase (SOD), glutathione peroxidase (GPx)
and catalase (CAT) is altered (Faure et al. 2008). The
single-nucleotide polymorphisms in genes coding for
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antioxidant enzymes may be associated with decreased or
impaired ROS detoxification and increase oxidative dam-
age (Flekac et al. 2008). Molecular variants of antioxidant
enzymes are potential risk factors for chronic complica-
tions of diabetes (Forsberg et al. 2001; Houldsworth et al.
2015).
Human glutathione peroxidase (GPX) is an antioxidant
enzyme expressed in blood vessels. Its main role is pro-
tecting cells against oxidative damage by reducing hydro-
gen peroxide and organic peroxidases to H2O2 with
reduced glutathione (Suzen et al. 2010). The most common
isoform of GPS family is GPX1, a selenium-dependent
enzyme encoded by Gpx1 gene. The gene is located on
chromosome 3p21 and contains two exons. One of its
polymorphisms is a leucine to proline change at codon
position 198 (Jefferies et al. 2005). The Leu allele was
reported to be associated with genetic susceptibility to
coronary atherosclerosis in type 2 diabetic patients (Ne-
moto et al. 2007).
The purpose of the present study was to evaluate the
association of the Pro197Leu polymorphism in the Gpx1
gene with diabetic neuropathy in type 2 diabetes patients.
Our hypothesis was that this polymorphism in the gene
encoding antioxidant enzyme could be associated with
diabetes and/or its complications.
Materials and Methods
Subjects
The study population included 1244 unrelated T2DM
patients, consecutively enrolled between 2008 and 2014
from the Departments of Nephrology and Cardiology of
Medical University of Lublin. All subjects were Cau-
casians of Polish origin. The type 2 diabetes was diagnosed
according to American Diabetes Association criteria
(American Diabetes Association 2013). Diagnosis was
based on one or more of the following conditions: classic
symptoms of hyperglycemia (polyuria, polydipsia, weight
loss), random plasma glucose C 11 mmol/L or fasting
plasma glucose C 7 mmol/L or and/or treatment with
antidiabetic agents. Age at diagnosis of T2DM
was[ 35 years in all subjects. The mean duration of dia-
betes was 12.8 years (range 7–31). Cardiovascular disease
was diagnosed in 888 patients (71 %) as one or combina-
tion of pathological states: ischemic heart disease (chronic
coronary heart disease and/or acute coronary syndromes),
congestive heart failure or ischemic cerebral stroke. Clin-
ical manifestations of CVD were confirmed by relevant
biochemical, radiographic, echocardiographic and vascular
diagnostic criteria. Among the patients 946 individuals
(76 %) were hypertensive, according to World Health
Organization criteria. Diabetic nephropathy was diagnosed
clinically in the presence of persistent albumin-
uria C 300 mg/24 h in at least two consecutive determi-
nations in the absence of hematuria or infection. Diabetic
retinopathy was diagnosed according to the Early Treat-
ment Diabetic Retinopathy Study (ETDRS) criteria: the
presence of microaneurysms, hemorrhages, cotton wool
spots, intraretinal microvascular abnormalities, hard exu-
dates, venous beading and new vessels. In T2DM patient
group, 406 individuals (32.6 %) had diabetic neuropathy.
Neurological assessment included evaluation of neuro-
pathic symptoms and deficits. Diabetic neuropathy was
diagnosed by clinical neurological examination and elec-
tromyography (Viking Select EMG System, Nicolet
Biomedical, USA) according to the recent guidelines
(Tesfaye et al. 2010).
Healthy control subjects (n = 730) with normal ECG
and no clinical signs of renal, cardiovascular and neuro-
logical disease were randomly recruited among hospital
staff and blood bank donors who underwent health exam-
ination. They were asked about risk factors, existing dis-
eases and medication intake. Subjects with positive family
history of DM or CVD in first degree relatives were
excluded. Before the inclusion into the study, a written
informed consent for genotyping was obtained from all
patients and controls in accordance with principles of the
1964 Declaration of Helsinki. The institutional ethics
committee approved the protocol of the study.
Determination of Gpx1 Pro198Leu Genotype
Genomic DNA was extracted from peripheral blood
leukocytes obtained by the standard procedure. The
Pro198Leu polymorphism in the Gpx1 gene (rs1050450,
198C[T) was analyzed by amplification of 337-bp DNA
fragment by polymerase chain reaction (PCR). The fol-
lowing primers were used for amplification reaction: sense
primer 50-TGTGCCCCTACGGTACA-30 and antisense
primer 50-CCAAATGACAATGACACAGG-30 (Hu and
Diamond 2003). Genomic DNA (300 ng) was amplified in
a final volume of 30 ll using the following conditions:
initial denaturation at 95 C for 5 min, followed by 35
cycles of 94 C for 30 s, annealing at 58 C for 30 s and
extension at 72 C for 2 min. A final extension step was at
72 C for 10 min. The PCR product containing polymor-
phic site was 338-bp fragment. Ten ll of the PCR product
were digested overnight at 37 C with 5 U of Apa I
restriction endonuclease (Thermo Fisher Scientific, Wal-
tham, MA), and resulting fragments were separated on a
2 % agarose gel. The fragment sizes were 259 ? 79 bp for
wild type (CC), 338 ? 258 ? 79 bp for CT heterozygote
and 338-bp undigested fragment for polymorphic variant
(TT). The quality of genotyping was controlled by using
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blind DNA duplicates for random samples. In addition, 20
samples were randomly selected for each genotype, and the
PCR products were sequenced in CEQ 8000 Genetic
Analysis System (Beckman Coulter, England). There was a
100 % concordance between genotyping assays.
Statistical Analysis
Statistical calculations were performed using Statistical
Package for Social Sciences version 11.0 for Windows
(SPSS, Inc., Chicago, IL, USA). For baseline characteris-
tics, the normally distributed continuous variables are
presented as mean ± SD. The Hardy–Weinberg equilib-
rium was assessed using a V2 test with 1 degree of free-
dom. Genotype distribution and allele frequencies were
compared between groups using a Pearson v2 test of
independence with 2 9 2 contingency and z statistics.
Analysis of variance (ANOVA) was used to compare the
distribution of quantitative biochemical parameters. Pear-
son V2 test and Mann–Whitney test were used for com-
paring discrete and continuous variables. For significant
allelic and genotyping associations, the adjusted odds ratios
(ORs) with corresponding 95 % confidence intervals (CIs)
were calculated. In the T2DM DPN? patient group, the
frequency of the Pro198Leu T allele was 0.37. The study
had 97.2 % power (a = 0.05) to detect an association (OR
vs DPN- 1.55, 95 % CI 1.30–1.85). An interaction of the
polymorphism with various risk factors was examined with
unconditional model of multiple logistic regression analy-
sis. All tests were two-sided with statistical significance set
at p\ 0.05.
Results
In this case–control study, the Pro198Leu polymorphism
(rs1050450) in the Gpx1 gene was genotyped in 1244
patients with T2DM (33 % had diabetic neuropathy) and
730 healthy control subjects. Baseline demographic and
clinical characteristics of T2DM patients are summarized
in Table 1. Age at study and gender did not statistically
differ between patients with diabetic neuropathy and those
without it. HbA1c was higher in DPN subgroup when
compared with patients without DPN (p = 0.028). As
expected, the diabetes duration was longer in the DPN
subgroup than in patients without DPN (p\ 0.0001). The
DPN subgroup had a higher prevalence of other
microvascular complications (p\ 0.0001). The patients
with DPN were about 4 years younger at diabetes onset
than those without DPN (p\ 0.0001). The prevalence of
cardiovascular disease differed significantly between the
two subgroups (p = 0.027).
The prevalence of the Pro198Leu (C/T) genotype and
allele frequencies in type 2 diabetes patients and controls is
presented in Table 2. The observed frequencies of the T
allele and TT genotype were different between these
groups (OR 1.16, p = 0.041 and OR 1.40, p = 0.034,
respectively). We next compared distribution of alleles and
genotypes between patients with DPN and patients without
it. A significant increase in the T allele frequency was
observed in DPN patients compared to those without DPN
(37vs 27 %, p = 0.0003) (Table 3). The variant T allele
was associated with a higher risk of developing DPN (OR
1.55, p\ 0.0001). Both genotypes, the homozygous TT
and heterozygous CT, had even greater effect (OR 1.89,
p = 0.0008 and OR 1.78, p\ 0.0001, respectively). The
association remained significant after correction for age,
disease duration, HbA1c and BMI. When distribution of
the T allele was compared between DPN? and
DPN- subgroups of patients and controls, for DPN? OR
was 1.54, p\ 0.0001 and for DPN- OR 1.00, p = 0.9947.
In logistic regression analysis regarding the presence of
DPN and different variables: age, gender, duration of dia-
betes, hypertension, total cholesterol, HDL cholesterol,
triglycerides and BMI no statistical associations were
observed (Table 4).
Since the Pro198Leu polymorphism in the Gpx1 gene
was previously reported to be associated with cardiovas-
cular disease in diabetic subjects, we checked the distri-
bution of this polymorphism in subgroups of CVD ? and
CVD - patients. No statistically significant differences
were observed between the subgroups. In CVD ? patients
versus CVD - the OR for T allele was 0.97 (0.80–1.17),
p = 0.767 and for TT genotype 0.99 (0.66–1.47),
p = 0.969.
Discussion
Diabetic peripheral neuropathy is common complication of
diabetes with complex, multifactorial pathogenetic mech-
anisms (Vinik et al. 2013). Analysis of candidate gene
variants in DPN could be useful in identifying patients
susceptible to development of this complication. Oxidative
stress is involved in the development of diabetes and its
complications (Robertson et al. 2004; Vincent et al. 2004).
Several studies have shown that the Gpx1 Pro198Leu
polymorphism increases the incidence of oxidative stress-
related diseases (Tang et al. 2008; Matsuno et al. 2011;
Chen et al. 2012; Ramprasath et al. 2012; Cao et al. 2014).
In the present study, we identified an association
between the Pro197Leu polymorphism in the Gpx1 gene
and diabetic peripheral neuropathy in type 2 diabetes
patients. The main finding is that the T allele of the
Pro198Leu polymorphism might increase risk of DPN. The
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similar result was obtained by Tang et al. (2012). In a study
of two independent samples of Caucasian patients with
diabetes mellitus, the authors observed a significant asso-
ciation between the T allele of the Pro198Leu
polymorphism and peripheral neuropathy. This association
was independent of other risk factors. In a small Japanese
study of 173 type 2 diabetes patients, the Pro198Leu
polymorphism in Gpx1 gene was found to be a
Table 1 Demographic and
clinical profile of studied
subjects
Variable T2DM with DPN T2DM without DPN P valuea
(n = 406) (n = 838)
Male (%) 194 (47.8) 400 (47.7) 0.973
Age at study (years) 63 ± 12.4 62.9 ± 13.5 0.900
Age at diabetes onset (years) 48.3 ± 15.8 52 ± 14.3 \0.0001
Diabetes duration (years) 14.9 ± 9.7 10.7 ± 8.7 \0.0001
Cardiovascular disease (%) 310 (76.3) 578 (69.3) 0.027
Essential hypertension (%) 322 (80) 624 (75.7) 0.155
Other MV complications (%) 320 (78.8) 378 (45.1) \0.0001
Family history of diabetes (%) 174 (42.9) 341 (47) 0.460
HbA1c (%) 8.3 ± 1.9 8.1 ± 1.5 0.028
Total cholesterol (mmol/l) 4.6 ± 1.7 4.4 ± 1.9 0.072
HDL cholesterol (mmol/l) 1.2 ± 0.45 1.2 ± 0.38 1.000
LDL cholesterol (mmol/l) 2.8 ± 1.05 2.8 ± 1.09 1.000
Triglycerides (mmol/l) 1.8 ± 1.08 1.8 ± 1.15 1.000
BMI (kg/m2) 29.6 ± 6.5 29.1 ± 5.2 0.144
T2DM type 2 diabetes mellitus, DPN diabetic peripheral neuropathy, MV microvascular
Values are presented as mean ± SD (continuous characteristics) or as numbers with percent in parentheses
(discrete characteristics)
a Pearson’s v2 test for categorical variables, Mann–Whitney test for continuous variables
Table 2 Genotype and allele distribution of Pro198Leu polymorphism in Gpx1 gene in T2DM patients and controls
Genotypes Alleles OR (95 % CI)
N CC CT TT C T TT genotypea T allele
T2DM patients 1244 635 (51) 460 (37) 149 (12) 0.70 0.30 1.40 (1.02–1.93) 1.16 (1.00–1.34)
p = 0.034 p = 0.041
Controls 730 396 (54) 268 (37) 66 (9) 0.73 0.27 Ref. Ref.
T2DM type 2 diabetes mellitus
Genotype distributions are shown as numbers (%)
a Calculated versus CC genotype
Table 3 Genotype and allele distribution of Pro198Leu polymorphism in Gpx1 gene in T2DM patients with and without DPN
Genotypes Alleles OR (95 % CI)
N CC CT TT C T TT genotypea CT genotypea T allele
T2DM with DPN 406 167 (41) 179 (44) 60 (15) 0.63 0.37 1.89 (1.30–2.74) 1.78 (1.38–2.30) 1.55 (1.30–1.85)
p = 0.0008 p\ 0.0001 p\ 0.0001
T2DM without DPN 838 468 (56) 281 (33) 89 (11) 0.73 0.27 Ref. Ref. Ref.
Genotype distribution is shown as numbers (%)
T2DM type 2 diabetes, DPN diabetic peripheral neuropathy
a OR calculated versus CC genotype. The ORs adjusted for age, disease duration, HbA1c and BMI: for TT genotype OR 1.56 (1.04–2.63),
p = 0.011; for CT genotype OR 1.49 (0.71–2.4), p = 0.008; for T allele 1.37 (0.66–2.51), p = 0.001. The study had 97.2 % power (a = 0.05) to
detect an association (OR versus DPN- 1.55, 95 % CI 1.30–1.85)
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predisposing factor in distal symmetric polyneuropathy and
macrovascular disease (Matsuno et al. 2011). Our results
are not consistent with a previous study performed in a
Polish population that showed no association between the
Gpx1 Pro198Leu polymorphism and distal symmetric
polyneuropathy in patients with type 2 diabetes (Kasznicki
et al. 2016). It is difficult to explain this discrepancy
between studies. Possibly part of it might be a number of
patients studied. Our study involved 1244 T2DM patients
versus 245 in Kasznicki et al. study. Diabetic neuropathy is
a complex condition in which it might be difficult to
demonstrate an impact of a single polymorphism. An
interactive effect of several factors may lead to underesti-
mation or overestimation of a role of given polymorphism
in determining the phenotype. What’s more, control sub-
jects are considered free of diabetic neuropathy by medical
history, lack of neurological deficits and laboratory
examinations. This does not exclude subjects who might be
affected by subclinical neuropathy.
In our study, there was no significant association with
the polymorphic variant of the Pro198Leu with cardio-
vascular disease. This is in line with other reports from
Caucasian populations (Tang et al. 2012; Kasznicki et al.
2016). Such association was reported in the studies from
Asia (Hamanishi et al. 2004; Tang et al. 2008). This dis-
crepancy may be due to the ethnic and baseline charac-
teristics differences between populations.
Some studies reported an association with Pro198Leu
polymorphism in Gpx1 with type 2 diabetes (Ramprasath
et al. 2012). We also observed an association with the
Pro198Leu T allele with diabetes itself when compared to
healthy control subjects. In a Japanese study, the Pro198-
Leu polymorphism was associated with the development of
diabetic polyneuropathy but not the onset of diabetes itself
(Matsuno et al. 2011). A similar result was observed in the
study of Vats et al. (2015).
The mechanism of the observed effect of Gpx1 gene
polymorphism on susceptibility to diabetic neuropathy is
unknown. Several studies confirmed the association with
Pro198Leu with Gpx1 activity (Ravn-Haren et al. 2006;
Hansen et al. 2009). Changing the capacity of antioxidant
enzyme may lead to increased oxidative damage associated
with the T allele. Previous studies have shown a link
between Gpx activity and LDL oxidation (Rosenblat and
Aviram1998). This was found to be important in the eti-
ology of microvasculitis and local ischemic injury of
peripheral nerves (Said et al. 2003). Also, increased
OxLDL/apoB ratio was associated with peripheral neu-
ropathy in type 2 diabetes (Tsuzura et al. 2004). One of the
possible pathophysiological mechanisms involved in Gpx1
role in peripheral neuropathy might be an impaired
microcirculation in the peripheral nerves caused by vas-
cular endothelial dysfunction associated with oxidative
stress (Hamanishi et al. 2004). A direct nerve damage
resulting from elevated oxidative stress is also possible
(Oyenihi et al. 2015).
Our study has some limitations. It is a retrospective
case–control study; thus, a selection bias cannot be
excluded. To limit this bias, we included consecutive
patients in the study and tried to adjust for known con-
founding risk factors. We were unable to score the
severity of neuropathy in the entire patient cohort and
therefore to perform subgroup analyses in patients with
different severity scores. We also did not examine the
association between Gpx1 genotype and enzyme activity
in our patient cohort and we plan to analyze this in our
further work. Also, we examined only one polymorphism
in the Gpx1 gene. The strength of our study is that all
patients and controls are of the same ethnic origin. Fur-
thermore, all subjects were examined in a standardized
manner, with well defined diagnostic criteria and geno-
typing was performed blind with respect to case–control
status.
In conclusion, our findings suggest that Gpx1 Pro198-
Leu genotypes are significantly associated with the risk of
diabetic peripheral neuropathy in patients with T2DM.
These results require replication in future studies. The
effect on observed genetic susceptibility is modest but
might be important in the presence of other genetic factors.
The study provides new clinically relevant information
regarding genetic determinants of susceptibility to diabetic
neuropathy.
Acknowledgments This study was supported by research Grants DS
379/14 and DS 379/15 (MB) from Medical University of Lublin.
Compliance with Ethical Standards
Conflict of interest The authors declare that they have no conflict of
interest.
Table 4 Multiple logistic regression analysis
Variable OR (95 % CI) P
Age 1.18 (0.83–1.39) 0.078
Gender 1.12 (0.91–1.22) 0.137
Age at diabetes onset 1.09 (0.91–1.32) 0.091
Disease duration 0.98 (0.89–1.06) 0.082
Cardiovascular disease 1.27 (0.85–1.92) 0.144
Hyperlipidemia 1.36 (0.69–2.82) 0.262
HbA1c 1.15 (0.99–1.41) 0.084
BMI 1.02 (0.96–1.09) 0.832
TT genotypea 2.13 (1.42–4.03) 0.009
An unconditional model of multiple logistic regression analysis was
used for interaction of the polymorphism with various risk factors
a Pro198Leu polymorphism
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